- Overview
- Properties
- Related Genes
- Pathways
- Related Drugs
- Related Diseases
- Datasets
- Downloads/LinkOuts
Overview
| Trade Names: | Biocoryl; Novocainamid; Novocainamide; Novocaine Amide; Novocamid; Procainamide Hcl; Procaine Amide; Procamide; Procan; Procan Sr; Procanbid; Procapan; Promine; Pronestyl; Pronestyl-Sr |
|---|---|
| PharmGKB Accession Id: | PA451108 |
Description
A derivative of procaine with less CNS action. PubChem (source: Drug Bank)
Indication
For the treatment of life-threatening ventricular arrhythmias. (source: Drug Bank)
ATC Therapeutic Category
- C01BA:Antiarrhythmics, class Ia
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Procainamide is sodium channel blocker. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. (source: Drug Bank)
Pharmacology
Procainamide is an agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Procainamide appears to be similar to that of procaine and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected. (source: Drug Bank)
Food Interactions
Avoid alcohol.
Take with food to reduce irritation.
(source:
Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Biotransformation
Hepatic (source: Drug Bank)
Protein Binding
15 to 20% (source: Drug Bank)
Absorption
75 to 95% (source: Drug Bank)
Toxicity
LD<sub>50</sub>=95 mg/kg (rat, IV); LD<sub>50</sub>=312 mg/kg (mouse, oral); LD<sub>50</sub>=103 mg/kg (mouse, IV); LD<sub>50</sub>=250 mg/kg (rabbit, IV) (source: Drug Bank)
Isomeric SMILES Code:
CCN(CC)CCNC(=O)c1ccc(cc1)N (source: Drug Bank)
The following genes are in curated knowledge about this drug.
| Gene | Relationship | Evidence | |
|---|---|---|---|
|
KCNH2 |
|
Publications |
|
NAT2 |
|
Publications |
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| DNMT1 |
|
(source: Drug Bank) |
| SCN5A |
|
(source: Drug Bank) |
PharmGKB Curated Pathways
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| amiodarone |
|
Amiodarone increases serum levels and toxicity of procainamide (source: Drug Bank) |
| cimetidine |
|
The histamine H2-receptor antagonist increases the effect of procainamide (source: Drug Bank) |
| ciprofloxacin |
|
The quinolone increases the effect of procainamide (source: Drug Bank) |
| cisapride |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| donepezil |
|
Possible antagonism of action (source: Drug Bank) |
| galantamine |
|
Possible antagonism of action (source: Drug Bank) |
| levofloxacin |
|
The quinolone increases the effect of procainamide (source: Drug Bank) |
| mesoridazine |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| ofloxacin |
|
The quinolone increases the effect of procainamide (source: Drug Bank) |
| quinidine |
|
Quinidine increases the effect of procainamide (source: Drug Bank) |
| ranitidine |
|
The histamine H2-receptor antagonist increases the effect of procainamide (source: Drug Bank) |
| rivastigmine |
|
Possible antagonism of action (source: Drug Bank) |
| terfenadine |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| thioridazine |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| trimethoprim |
|
Trimethoprim increases serum levels of procainamide (source: Drug Bank) |
| vardenafil |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| ziprasidone |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Curated Phenotype Datasets
These datasets are sorted alphabetically by title.
- Drug-Induced Long QT Intervals
- PD
Submitted by Dan Roden, MD involving ADRB1, ADRB2, KCNE1, KCNE2, KCNH2, KCNQ1, SCN5A, almokalant, amiodarone, amitriptyline, bretylium, bupivacaine, cisapride, disopyramide, dofetilide, encainide, fluconazole, haloperidol, hydroquinidine, isoflurane, itraconazole, ketoconazole, lithium, loratadine, metoclopramide, nortriptyline, procainamide, quinidine, sematilide, sotalol, sulfamethoxazole, thioridazine, trimethoprim, , Long QT Syndrome, Proarrhythmia and Torsades de Pointes - SLC22A2 Functional Protein Variants
- FA
Submitted by Kathleen M. Giacomini, PhD involving SLC22A2, , cimetidine, metformin, MPP+, phenformin, procainamide and quinidine - Xenopus expression of variant SLC22A2 proteins
- FA
Submitted by Kathleen M. Giacomini, PhD involving SLC22A2, , metformin, MPP+, phenformin, procainamide and quinidine
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
Downloads
You must sign in before you can download data.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.